In a prospective study involving 26 individuals with locally advanced or metastatic NSCLC, EGFR‐TKI therapy combined with individualized thoracic radiotherapy exhibited a favorable safety profile and achieved promising outcomes (mOS: 21.8 months).33 Here, EGFR is linked to non-small cell lung carcinoma.